A Phase I, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Retlirafusp alfa (Primary)
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 15 Nov 2021 Planned number of patients changed from 112 to 206.
- 15 Nov 2021 Planned End Date changed from 1 Jun 2020 to 31 Dec 2022.
- 15 Nov 2021 Planned primary completion date changed from 1 Nov 2019 to 31 Dec 2022.